Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The Phase 2 expansion Part B of the study assessed the objective response rate (primary endpoint) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody ...

Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also improved rates of complete ...

Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple ...

With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier Nataf, global head of oncology at Sanofi, said: ...